amryt-logo.png
Amryt Supports FH Awareness Day – September 24, 2022
September 23, 2022 07:00 ET | Amryt Pharma plc
Amryt Supports FH Awareness Day – September 24, 2022 DUBLIN, Ireland, and Boston MA, September 23, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company...
amryt-logo.png
CHMP adopts positive opinion for Mycapssa® for the treatment of Acromegaly
September 16, 2022 07:30 ET | Amryt Pharma plc
CHMP adopts positive opinion for Mycapssa® for the treatment of Acromegaly Positive opinion based on MPOWERED Phase 3 trial DUBLIN, Ireland, and Boston MA, September 16, 2022, Amryt (Nasdaq:...
amryt-logo.png
Amryt Announces New Patent for Mycapssa®
September 13, 2022 07:00 ET | Amryt Pharma plc
Amryt Announces New Patent for Mycapssa® DUBLIN, Ireland, and Boston MA, September 13, 2022 Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring,...
amryt-logo.png
Amryt Receives Marketing Authorisation Approval and Orphan Drug Designation for Filsuvez® in Great Britain
September 08, 2022 07:00 ET | Amryt Pharma plc
Amryt Receives Marketing Authorisation Approval and Orphan Drug Designation for Filsuvez® in Great Britain UK MHRA approval follows on from recent European Commission approval of Filsuvez® DUBLIN,...
amryt-logo.png
Amryt to Present Data from MPOWERED Phase 3 Trial of Mycapssa® (oral octreotide) at ENEA 2022
September 07, 2022 07:00 ET | Amryt Pharma plc
Amryt to Present Data from MPOWERED Phase 3 Trial of Mycapssa® (oral octreotide) at ENEA 2022 DUBLIN, Ireland, and Boston MA, September 7, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage...
amryt-logo.png
Amryt Reports Record Q2 2022 Results
August 04, 2022 07:00 ET | Amryt Pharma plc
Amryt Reports Record Q2 2022 Results 9.2% YoY revenue growth in Q2 to $68.5M 35.3% YoY revenue growth in Q2 excluding impact of a sporadic LATAM order in Q2 2021 7.8% growth in metreleptin...
amryt-logo.png
Amryt to Report Q2 2022 Results on August 4, 2022
July 21, 2022 07:00 ET | Amryt Pharma plc
DUBLIN, Ireland, and Boston MA, July 21, 2022, Amryt (Nasdaq: AMYT) a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for...
amryt-logo.png
Amryt Receives Orphan Drug Designation from the FDA for Mycapssa® (oral octreotide) for the Treatment of Carcinoid Syndrome
July 14, 2022 07:00 ET | Amryt Pharma plc
Amryt Receives Orphan Drug Designation from the FDA for Mycapssa® (oral octreotide) for the Treatment of Carcinoid Syndrome DUBLIN, Ireland, and Boston MA, July 14, 2022, Amryt (Nasdaq: AMYT), a...
amryt-logo.png
Amryt Presents New Analyses from the EASE Phase 3 Trial in Epidermolysis Bullosa at SPD 2022
July 07, 2022 07:00 ET | Amryt Pharma plc
Amryt Presents New Analyses from the EASE Phase 3 Trial in Epidermolysis Bullosa at SPD 2022 - Key highlights include efficacy of Oleogel-S10 (birch triterpenes) on accelerated wound healing, data on...
amryt-logo.png
Results of Annual General Meeting
July 01, 2022 07:00 ET | Amryt Pharma plc
DUBLIN, Ireland, and Boston MA, July 1, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel treatments for rare...